Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network
Daxor (Nasdaq: DXR), the global leader in blood volume measurement technology, has announced the expansion of its Blood Volume Analysis (BVA) technology. A 339-bed community hospital in northwest Mississippi, part of the Mid-South's largest integrated delivery network, has acquired a BVA analyzer for outpatient heart failure care. This acquisition is expected to enhance patient outcomes in a region with access to specialized care and accelerate sales growth for Daxor.
The move is particularly significant given Mississippi's high heart disease death rate of 324.4 per 100,000 people, compared to the national average of 173.8. Daxor's BVA diagnostic provides 98% accurate actionable data to guide fluid management decisions, enabling personalized care plans for heart failure patients. This technology is important for proactive management, early intervention, and continuous monitoring, which can help prevent hospitalizations and reduce healthcare costs.
Daxor (Nasdaq: DXR), leader globale nella tecnologia di misurazione del volume sanguigno, ha annunciato l'espansione della sua tecnologia di Analisi del Volume Sanguigno (BVA). Un ospedale comunitario con 339 letti nel nord-ovest del Mississippi, parte della rete integrata di assistenza più ampia del Mid-South, ha acquisito un analizzatore BVA per cura ambulatoriale dell'insufficienza cardiaca. Si prevede che questa acquisizione migliori gli esiti dei pazienti in una regione con accesso a cure specializzate e acceleri la crescita delle vendite per Daxor.
La mossa è particolarmente significativa considerando l'elevato tasso di decessi per malattie cardiache nel Mississippi, pari a 324,4 per 100.000 persone, rispetto alla media nazionale di 173,8. La diagnosi BVA di Daxor fornisce 98% di dati attendibili e utilizzabili per guidare le decisioni di gestione dei fluidi, consentendo piani di cura personalizzati per i pazienti con insufficienza cardiaca. Questa tecnologia è importante per una gestione proattiva, intervento precoce e monitoraggio continuo, che può aiutare a prevenire ospedalizzazioni e ridurre i costi sanitari.
Daxor (Nasdaq: DXR), líder mundial en tecnología de medición del volumen sanguíneo, ha anunciado la expansión de su tecnología de Análisis de Volumen Sanguíneo (BVA). Un hospital comunitario de 339 camas en el noroeste de Misissipi, parte de la red de entrega integrada más grande del Mid-South, ha adquirido un analizador BVA para cuidado ambulatorio de la insuficiencia cardíaca. Se espera que esta adquisición mejore los resultados de los pacientes en una región con acceso a atención especializada y acelere el crecimiento de ventas para Daxor.
Este movimiento es particularmente significativo dado que la tasa de mortalidad por enfermedades cardíacas en Misissipi es de 324.4 por cada 100,000 personas, en comparación con el promedio nacional de 173.8. El diagnóstico BVA de Daxor proporciona 98% de datos precisos y útiles para guiar las decisiones de manejo de fluidos, permitiendo planes de cuidado personalizados para pacientes con insuficiencia cardíaca. Esta tecnología es importante para la gestión proactiva, la intervención temprana y el monitoreo continuo, lo que puede ayudar a prevenir hospitalizaciones y reducir los costos de atención médica.
닥소르(Daxor, Nasdaq: DXR)는 혈액량 측정 기술의 글로벌 리더로서 혈액량 분석(BVA) 기술의 확장을 발표했습니다. 미시시피 북서부에 위치한 339개 침대의 지역사회 병원이 BVA 분석기를 외래 심부전 치료를 위해 인수했습니다. 이번 인수는 전문 치료에 접근할 수 있는 지역에서 환자 결과를 개선하고 닥소르의 판매 성장 가속화에 기여할 것으로 예상됩니다.
미시시피의 심장병 사망률이 인구 10만 명당 324.4명으로, 전국 평균 173.8명에 비해 높은 점을 고려할 때 이 조치는 특히 중요합니다. 닥소르의 BVA 진단은 98% 정확한 실행 가능한 데이터를 제공하여 체액 관리 결정을 안내하고, 심부전 환자를 위한 개인화된 치료 계획을 가능하게 합니다. 이 기술은 적극적인 관리, 조기 개입 및 지속적인 모니터링에 중요하며, 이는 입원을 예방하고 의료 비용을 줄이는 데 도움을 줄 수 있습니다.
Daxor (Nasdaq: DXR), leader mondial de la technologie de mesure du volume sanguin, a annoncé l'expansion de sa technologie d'Analyse du Volume Sanguin (BVA). Un hôpital communautaire de 339 lits dans le nord-ouest du Mississippi, faisant partie du plus grand réseau de services intégrés du Mid-South, a acquis un analyseur BVA pour soins ambulatoires de l'insuffisance cardiaque. Cette acquisition devrait améliorer les résultats des patients dans une région ayant accès à des soins spécialisés et accélérer la croissance des ventes pour Daxor.
Cette initiative est particulièrement significative compte tenu du taux de mortalité par maladies cardiaques élevé au Mississippi, qui s'élève à 324,4 pour 100 000 habitants, par rapport à la moyenne nationale de 173,8. Le diagnostic BVA de Daxor fournit 98% de données exploitables et précises pour orienter les décisions de gestion des fluides, permettant ainsi des plans de soins personnalisés pour les patients souffrant d'insuffisance cardiaque. Cette technologie est essentielle pour une gestion proactive, une intervention précoce et un suivi continu, ce qui peut aider à prévenir les hospitalisations et à réduire les coûts de la santé.
Daxor (Nasdaq: DXR), der weltweit führende Anbieter von Technologien zur Messung des Blutvolumens, hat die Erweiterung seiner Blutvolumenanalyse-Technologie (BVA) bekannt gegeben. Ein Gemeinschaftskrankenhaus mit 339 Betten im Nordwesten von Mississippi, das Teil des größten integrierten Leistungserbringer-Netzwerks im Mittleren Süden ist, hat einen BVA-Analyzer für ambulatorische Herzinsuffizienzversorgung erworben. Diese Anschaffung soll die Patientenergebnisse in einer Region mit Zugang zu spezialisierten Behandlungen verbessern und das Umsatzwachstum von Daxor beschleunigen.
Dieser Schritt ist besonders bedeutend, angesichts der hohen Sterblichkeitsrate durch Herzkrankheiten in Mississippi von 324,4 pro 100.000 Menschen im Vergleich zum nationalen Durchschnitt von 173,8. Die BVA-Diagnose von Daxor liefert 98 % genau verwertbare Daten, um Entscheidungen zur Flüssigkeitssteuerung zu treffen, was personalisierte Behandlungspläne für Patienten mit Herzinsuffizienz ermöglicht. Diese Technologie ist wichtig für ein proaktives Management, frühzeitige Intervention und kontinuierliche Überwachung, was helfen kann, Krankenhausaufenthalte zu vermeiden und die Gesundheitskosten zu senken.
- Expansion of BVA technology through new analyzer acquisition
- Projected accelerated sales growth for the rest of the year
- BVA diagnostic provides 98% accurate actionable data for fluid management decisions
- Technology enhances outpatient heart failure care, potentially reducing hospitalizations and healthcare costs
- None.
Insights
The acquisition of the BVA analyzer by a community hospital in Mississippi represents a positive development for Daxor (Nasdaq: DXR). This sale not only contributes to immediate revenue but also signals potential for accelerated sales growth in the coming months. The expansion into rural healthcare markets, particularly in regions with high heart disease mortality rates, opens up a significant market opportunity for Daxor.
From a financial perspective, the company's focus on outpatient care aligns well with the healthcare industry's shift towards cost-effective, preventative treatments. This strategy could lead to increased demand for BVA analyzers, potentially driving long-term revenue growth. However, investors should monitor the pace of adoption and any associated costs of expanding into new markets to fully assess the impact on Daxor's financial performance.
Daxor's Blood Volume Analysis (BVA) technology represents a significant advancement in heart failure management, especially in outpatient settings. The 98% accuracy in guiding fluid management decisions is a standout feature that could revolutionize personalized care plans for heart failure patients. This level of precision is important in a state like Mississippi, where the heart disease death rate (324.4 per 100,000) is nearly double the national average (173.8 per 100,000).
The adoption of BVA technology in rural settings is particularly impactful, as it brings specialized diagnostic capabilities to areas traditionally underserved in healthcare. This could lead to earlier interventions, reduced hospitalizations and improved patient outcomes. The potential for BVA to become a standard of care in heart failure management could drive further market expansion for Daxor, especially if clinical data continues to support its efficacy in improving patient outcomes and reducing healthcare costs.
Daxor's expansion into rural healthcare markets with its BVA technology demonstrates a strategic move to address an underserved market segment. The focus on outpatient care aligns with the broader healthcare trend of shifting towards preventative and community-based care models. This positioning could give Daxor a competitive edge in the medical device market, particularly in regions with high heart disease prevalence.
The company's ability to penetrate integrated delivery networks is noteworthy, as these networks often have significant purchasing power and influence over regional healthcare practices. If Daxor can leverage this initial sale to expand within the network, it could lead to substantial market share growth. However, the success of this strategy will depend on Daxor's ability to demonstrate clear clinical and economic benefits of BVA technology, as well as effectively navigate the complex decision-making processes within large healthcare systems.
Community Hospital Purchases BVA Analyzer With Focus on Improving Outpatient Heart Failure Care
Oak Ridge, TN, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces the expansion of its blood volume analysis (BVA) technology through the acquisition of the BVA analyzer. This advancement not only enhances revenue streams, but also sets the stage for projected accelerated sales growth for the rest of the year.
A rural 339-bed community hospital in northwest Mississippi, part of the Mid-South's largest integrated delivery network, has acquired a BVA analyzer for outpatient heart failure care. This acquisition is critical for enhancing patient outcomes in a region where access to specialized care can be limited. In 2021, the United States recorded 173.8 heart disease deaths per 100,000 people, while Mississippi saw a notably higher rate of 324.4 deaths per 100,000. As a result, many hospitals in affected regions are seeking to enhance the quality of care by incorporating BVA testing.
“Outpatient heart failure care is essential for proactive management, early intervention, and continuous monitoring, which are key to preventing hospitalizations, improving patient outcomes, and reducing healthcare costs," said Michael Feldschuh, Daxor’s CEO and President. “Our BVA diagnostic provides
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100™ (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
What is the significance of Daxor's BVA analyzer acquisition for the Mississippi hospital?
How accurate is Daxor's BVA diagnostic for heart failure management?
What impact is the BVA analyzer expected to have on Daxor's (DXR) financial performance?
How does the heart disease death rate in Mississippi compare to the national average?
